About Translyx
Auckland-based clinical technology company — connecting diagnostics, digital pathology AI, and governed AI software for New Zealand and Oceania.
Our mission
Translyx Limited brings advanced diagnostic and clinical products to the New Zealand healthcare sector — giving clinicians and health services access to technologies that improve diagnostic accuracy, clinical decision-making, and patient outcomes.
The team combines deep expertise across diagnostics, laboratory medicine, clinical implementation, and healthcare supply. That experience informs how Translyx selects, evaluates, and introduces globally validated innovations — matching the right technology to the right clinical environment, across hospital, community, and research settings.
Translyx approaches product introduction at the system level. Diagnostic capability is not an isolated procurement decision — it shapes how clinicians make decisions, how labs operate, and how patients experience care.
One platform, one accountable brand
Translyx is the trusted bridge between global diagnostic innovation and local clinical adoption — a single public platform spanning partner products, governed clinical AI workflow capabilities, and diagnostic innovation, accountable for clinical implementation in New Zealand and Oceania.
The single platform
Translyx Limited
The accountable New Zealand company — clinical positioning, diagnostic adoption, local partnerships, and healthcare implementation across Oceania, under one brand.
Aiforia & Algoscope
Partner products
Aiforia digital pathology AI and Algoscope surgery-to-pathology workflow automation — partner products represented by Translyx, not Translyx-owned.
Capabilities under evaluation
Translyx Pipeline
Governed clinical AI workflow capabilities — AI Wrapper, Cloud Shield, Scribe, Trace, and ClinicalTriage — under evaluation and development, not publicly launched.
Aiforia and Algoscope are partner products represented by Translyx in New Zealand — not owned or developed by Translyx. Pipeline capabilities are under evaluation or development and are not publicly launched products.
Leadership
Dr Ehsan Ullah
Founding Director
Translyx Ltd was established in December 2025 by Dr Ehsan Ullah, an Auckland-based physician scientist and healthcare entrepreneur advancing clinical diagnostic solutions in New Zealand.
Globally, the diagnostic market is undergoing rapid transformation driven by emerging trends in antimicrobial resistance (AMR), sepsis diagnostics, point-of-care testing, endocrinology, cardiac markers, artificial intelligence, and precision medicine. These advances are reshaping clinical decision-making and patient outcomes, creating a clear and urgent need for experienced leadership to bring advanced diagnostic technologies onshore to meet local healthcare demands.
Dr Ullah brings an established professional profile at the intersection of clinical practice, laboratory medicine, and health technology innovation — including leadership roles across specialised diagnostics and digital health initiatives. His vision for Translyx is grounded in translating cutting-edge global diagnostic innovations into practical, high-impact solutions for the New Zealand healthcare system.
The Translyx senior leadership team includes healthcare professionals with over 50 years of collective experience across the in vitro diagnostics (IVD) market, pathology services, and next-generation molecular diagnostic solutions. The team is committed to building strategic partnerships and expanding access to high-quality, clinically meaningful diagnostic tools.
Translyx Ltd represents Dr Ullah's commitment to strengthening diagnostic capability in Aotearoa New Zealand — supporting clinicians, laboratories, and healthcare providers with advanced solutions that improve patient care and system resilience.
How we work
At Translyx Limited, we provide expert professional services and consultancy tailored to the healthcare and diagnostics sector. Drawing on our team's extensive expertise across biomedical sciences, digital pathology, artificial intelligence, molecular diagnostics, and translational innovation, we deliver strategic guidance on diagnostic implementation, technology adoption, assay development, targeted therapy development, and healthcare systems optimisation.
We also support learning and development initiatives that advance translational innovation and inform precision medicine. Through this integrated approach, we partner with organisations, innovators, and health systems to refine product strategies and accelerate the impact of novel healthcare solutions and technologies in New Zealand and globally.
Please contact us at ehsan.ullah@translyx.co or info@translyx.co for details.
Operational territory
Translyx operates primarily in New Zealand, with planned expansion into Australia and the broader Oceania region, including selected Pacific Island markets. The company works closely with local laboratories, hospitals, and healthcare providers to ensure diagnostic solutions are relevant, practical, and aligned with real clinical needs. Through regional partnerships and scalable distribution models, Translyx aims to strengthen diagnostic capability across Oceania while enabling efficient market access for international diagnostic innovators.
Primary
- New Zealand — national
Expanding
- Australia
- Pacific Island markets
Partner model
- Local labs and hospitals
- Academic research centres
- Manufacturer partnerships
Responsible AI & clinical governance
As AI enters diagnostic and evidence workflows, Translyx delivers solutions that are governed, reviewable, and honest about their boundaries. Governance, traceability, visible limitations, and reviewer gates are structural features of the workflow — not disclaimers added after the fact.
We make no implied regulatory endorsement, and we are explicit about what each solution does and does not do. Human oversight remains central: AI assists clinical judgement, it does not replace it.
- Reviewer gates & human oversight
- Field-level data protection
- Visible limitations, declared
- No implied regulatory endorsement
Work with Translyx
Speak with the team about diagnostic product evaluation, partner products, or the broader Translyx pipeline.